Cdd866

Manufactured by Novartis

The CDD866 is a laboratory equipment product manufactured by Novartis. It is designed to perform specific functions within a laboratory setting. The core function of this product is to facilitate data collection and analysis, but no further details on its intended use can be provided in an unbiased and factual manner.

Automatically generated - may contain errors

Lab products found in correlation

Cisplatin cis diamminedichloroplatinum 2, by Merck Group (1 mentions) Everolimus, by Novartis (1 mentions) Gdf11, by Thermo Fisher Scientific (1 mentions) Gdf 8, by R&D Systems (1 mentions) Mg132, by Merck Group (1 mentions) Activin a, by R&D Systems (1 mentions) 20s proteasome activity assay, by Merck Group (1 mentions)

2 protocols using cdd866

Bimagrumab and CDD866 Antibody Production

Check if the same lab product or an alternative is used in the 5 most similar protocols

Bimagrumab is a human, monoclonal antibody directed against ActRII and originally identified from the MorphoSys HuCal phage library. CDD866 is a murinized version of bimagrumab, where the human Fc region of the antibody has been replaced by a mouse Fc. CDD866 was produced in CHO cells at Novartis Pharma AG (Basel, Switzerland). Cisplatin (cis-diamminedichloro-platinum (II)) was purchased from Sigma Aldrich (catalog number 479306). Everolimus was synthesized at Novartis Pharma AG.

Hatakeyama S., Summermatter S., Jourdain M., Melly S., Minetti G.C, & Lach-Trifilieff E. (2016). ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skeletal Muscle, 6, 26.

+ Open protocol

+ Expand

Neonatal Rat Ventricular Myocyte Isolation and Treatment

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Neonatal rats were purchased from Charles River Laboratories, and NRVMs were isolated using previously published techniques (45 (link)). NRVMs were serum starved for 6 hours before 18-hour treatment, unless otherwise specified. The following reagents were used: activin A (0 to 100 ng/ml: 338 AC, R&D Systems), GDF11 (100 ng/ml: 120–11, PeproTech), GDF8 (100 ng/ml: 788G8, R&D Systems), CDD866 (0 to 100 μg/ml; Novartis), MG132 (10 μM; Sigma-Aldrich), and A01 (10 μM; Sigma-Aldrich). Proteasome activity was measured using the 20S Proteasome Activity Assay (MilliporeSigma).

Roh J.D., Hobson R., Chaudhari V., Quintero P., Yeri A., Benson M., Xiao C., Zlotoff D., Bezzerides V., Houstis N., Platt C., Damilano F., Lindman B.R., Elmariah S., Biersmith M., Lee S.J., Seidman C.E., Seidman J.G., Gerszten R.E., Lach-Trifilieff E., Glass D.J, & Rosenzweig A. (2019). Activin type II receptor signaling in cardiac aging and heart failure. Science translational medicine, 11(482), eaau8680.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!